Mirum Pharmaceuticals to Acquire Travere's Bile Acid Product Portfolio for $445M
Foster City, CA, July 17, 2023 (Business Wire) -- Mirum Pharmaceuticals and Travere Therapeutics have finalized a deal for the sale of Travere's bile acid product portfolio, including Cholbam® and Chenodal®, for patients with liver disease. The acquisition, valued at $445 million, strengthens Mirum's pipeline and reinforces its position in pediatric hepatology, while enabling Travere to focus on its pipeline of innovative medicines for rare diseases.
Read full article here.